Ursolic Acid

Ursolic acid is a pentacyclic triterpenoid that exerts anticancer and anti-inflammatory effects by inhibiting NF-κB and STAT3 signaling, inducing mitochondria-mediated apoptosis, and suppressing COX-2 and MAPK pathways. In preclinical prostate cancer models, intraperitoneal administration at 200 mg/kg twice weekly for six weeks significantly suppressed DU145 tumor growth in athymic nude mice, and a Phase I liposomal formulation trial demonstrated linear pharmacokinetics in humans, though no large randomized controlled trials have yet confirmed clinical efficacy.

Origin & History

Ursolic acid is a pentacyclic triterpenoid secondary metabolite distributed widely across the plant kingdom, with particularly high concentrations in the waxy coatings of apple peels, rosemary leaves, holy basil, Prunella vulgaris, and Ilex hainanensis. It occurs naturally in temperate and subtropical flora across Europe, Asia, and the Americas, accumulating as a surface wax and protective metabolite in fruit skins, leaf cuticles, and bark. Commercial isolation typically involves solvent extraction and chromatographic purification from rosemary or apple pomace, both of which are abundant agricultural co-products.

Historical & Cultural Context

Ursolic acid's isolation is traced to the early 19th century when it was first characterized as a component of the waxy coatings on fruits and leaves, though the plants containing it—rosemary, apple, lavender, and self-heal (Prunella vulgaris)—had been used medicinally for centuries prior in European, Chinese, and Ayurvedic traditions. In Traditional Chinese Medicine, Prunella vulgaris (Xia Ku Cao) containing ursolic acid and related triterpenoids was employed as a heat-clearing, detoxifying herb for conditions including goiter, scrofula, and hypertension, while rosemary was used across Mediterranean cultures for digestive complaints, circulatory support, and preservation of meats. Apple peel, another rich source, was incorporated into folk remedies across multiple cultures for gastrointestinal and metabolic ailments, though the specific attribution of benefits to ursolic acid as a discrete molecule is a 20th-century development following advances in phytochemical isolation. Modern interest in ursolic acid as a targeted therapeutic agent emerged from systematic screening of triterpenoid libraries in the 1990s and 2000s, when its NF-κB and STAT3 inhibitory properties were characterized at the molecular level.

Health Benefits

- **Anticancer Activity**: Ursolic acid induces apoptosis in multiple cancer cell lines—including MDA-MB-231 breast, DU145/LNCaP prostate, and HepG2 hepatocellular carcinoma—through Bax upregulation, Bcl-2 downregulation, cytochrome C release, and caspase-9 cleavage, while also causing G1-phase cell cycle arrest.
- **Anti-inflammatory Effects**: By downregulating NF-κB and MAPK signaling cascades and inhibiting COX-2 and lipoxygenase enzymes, ursolic acid reduces prostaglandin synthesis, nitric oxide release, elastase activity, and pro-inflammatory cytokine expression in immune and epithelial cells.
- **Antioxidant Protection**: Ursolic acid scavenges reactive oxygen species and upregulates endogenous antioxidant defense enzymes, contributing to cytoprotection against oxidative stress implicated in cardiovascular, neurodegenerative, and metabolic diseases.
- **Cardioprotective Properties**: Through modulation of lipid peroxidation, inflammatory mediator suppression, and potential attenuation of atherosclerotic plaque formation pathways, ursolic acid demonstrates cardioprotective activity in preclinical models, supporting its traditional use in cardiovascular-protective botanical formulas.
- **Antidiabetic Potential**: Ursolic acid has been shown preclinically to improve insulin sensitivity, reduce fasting glucose, modulate adipogenesis, and inhibit alpha-glucosidase activity, suggesting utility in metabolic syndrome and type 2 diabetes management.
- **Antimicrobial Activity**: The compound disrupts microbial membrane integrity and modulates glycolysis and translational machinery in bacteria and fungi, exhibiting broad-spectrum antimicrobial effects that complement its role in plant defense systems.
- **STAT3 Pathway Inhibition**: Ursolic acid directly inhibits STAT3 phosphorylation and DNA binding, a mechanism particularly relevant to cancers with constitutively active STAT3 signaling, including triple-negative breast and hormone-refractory prostate cancers.

How It Works

Ursolic acid exerts its anti-inflammatory effects primarily through inhibition of NF-κB nuclear translocation and suppression of MAPK (ERK, JNK, p38) phosphorylation cascades, collectively reducing transcription of pro-inflammatory genes encoding COX-2, TNF-α, IL-6, and inducible nitric oxide synthase. In cancer cells, it triggers intrinsic mitochondrial apoptosis by upregulating the pro-apoptotic protein Bax, downregulating anti-apoptotic Bcl-2, releasing cytochrome C into the cytosol, and activating caspase-9 cleavage, while simultaneously inducing G1-phase cell cycle arrest through modulation of cyclin D1 and CDK inhibitor expression. Ursolic acid also blocks STAT3 tyrosine phosphorylation (Tyr705) and its subsequent dimerization and DNA binding, thereby suppressing transcription of oncogenic targets such as survivin, VEGF, and cyclin D1 in multiple tumor cell types. Additional molecular targets include tyrosine kinase receptors, lipoxygenase isoforms, alpha-glucosidase, and components of the glycolytic and translational machinery, underscoring the compound's pleiotropic pharmacological profile.

Scientific Research

The evidence base for ursolic acid is predominantly preclinical, comprising in vitro cell-line studies and rodent xenograft models, with very limited human clinical data available as of current literature. The most cited in vivo cancer study employed intraperitoneal ursolic acid at 200 mg/kg twice weekly for six weeks in athymic nude mice bearing DU145 prostate cancer xenografts, demonstrating significant tumor growth suppression without observable body weight toxicity, though sample sizes were not specified in available reports. A Phase I clinical trial evaluated a liposomal ursolic acid (LUA) formulation in healthy volunteers and solid tumor patients to establish maximum tolerated dose and characterize pharmacokinetics, finding a linear PK profile and identifying diarrhea and hepatotoxicity as dose-limiting toxicities; however, no efficacy endpoints, response rates, or hazard ratios were reported from this trial. No large-scale randomized controlled trials with statistically powered efficacy endpoints have been published, placing the current evidence firmly at the preclinical-to-early-clinical transition stage.

Clinical Summary

Clinical investigation of ursolic acid has thus far been restricted to a single published Phase I trial using a liposomal nanoformulation (LUA) designed to overcome the compound's poor aqueous solubility and oral bioavailability. This trial enrolled both healthy volunteers and patients with solid tumors to determine the maximum tolerated dose and dose-limiting toxicities, which were identified as diarrhea and hepatotoxicity at higher dose levels; pharmacokinetic analysis confirmed a linear dose-exposure relationship, suggesting predictable systemic behavior for the liposomal vehicle. No Phase II or Phase III trials reporting objective response rates, progression-free survival, or validated biomarker changes have been published, and no large dietary intervention studies quantifying ursolic acid intake and disease outcomes exist. Confidence in clinical efficacy remains low due to the absence of controlled efficacy data, and current findings should be interpreted as hypothesis-generating rather than practice-changing.

Nutritional Profile

Ursolic acid is a pure triterpenoid secondary metabolite and does not contribute macronutrient value (protein, carbohydrate, fat) in the amounts present in dietary sources. As a surface wax component in apple peels, it coexists with other pentacyclic triterpenoids including oleanolic acid, betulinic acid, and corosolic acid, as well as flavonoids, quercetin, and chlorogenic acid that may act synergistically. Estimated ursolic acid content ranges from approximately 50–700 mg per 100 g of dried rosemary leaf and up to 10–50 mg per 100 g of fresh apple peel, though values vary considerably by cultivar, growing conditions, and post-harvest handling. Oral bioavailability is significantly limited by poor aqueous solubility (log P approximately 6.5), resulting in low and erratic plasma concentrations after ingestion of conventional preparations; lipid-based or nanoparticulate delivery systems substantially improve systemic exposure in preclinical models.

Preparation & Dosage

- **Standardized Plant Extract (oral capsule/tablet)**: Most commercial supplements provide 50–150 mg of ursolic acid per dose, typically standardized from rosemary leaf extract (Rosmarinus officinalis) or apple peel extract; no universally accepted clinical dose has been established.
- **Liposomal Ursolic Acid (LUA)**: Investigated in Phase I clinical trials via intravenous infusion; dose escalation protocols were used to determine MTD; specific milligram thresholds were not publicly disclosed in available summaries.
- **Nanoparticle Formulations**: Preclinical nanoformulations (polymeric nanoparticles, solid lipid nanoparticles) have demonstrated enhanced bioavailability and antitumor effects in animal models but remain investigational and are not commercially standardized.
- **Rosemary Leaf Powder/Tea (Traditional)**: Traditionally consumed as an aqueous infusion or ethanolic tincture; ursolic acid content in dried rosemary ranges approximately 0.3–0.8% by dry weight, though bioavailability from whole-herb preparations is low due to poor water solubility.
- **Preclinical Efficacious Dose (reference only)**: 200 mg/kg intraperitoneally in murine models; not extrapolatable to human oral dosing without allometric scaling and bioavailability correction.
- **Timing Note**: No data exist on optimal dosing timing relative to meals; fat co-administration is theoretically beneficial given the lipophilic nature of the compound.

Synergy & Pairings

Ursolic acid demonstrates preclinical synergy with quercetin and other flavonoids through complementary inhibition of NF-κB and PI3K/Akt pathways, with quercetin also improving intestinal permeability and potentially enhancing ursolic acid absorption when co-administered. In oncology-relevant combinations, pairing ursolic acid with curcumin has been explored in preclinical models, where dual STAT3 and NF-κB blockade produces additive-to-synergistic antiproliferative effects against breast and hepatocellular carcinoma cell lines. Lipid-based co-formulation with phosphatidylcholine or incorporation into omega-3 fatty acid emulsions is a practical synergistic strategy that exploits the compound's lipophilicity to substantially increase oral bioavailability, representing the most evidence-supported formulation approach for enhancing clinical utility.

Safety & Interactions

At preclinical antitumor doses in mice (200 mg/kg IP), ursolic acid did not produce observable body weight loss or gross toxicity, suggesting a reasonable therapeutic window in rodent models; however, human safety data remain sparse and limited to a single Phase I liposomal trial. Dose-limiting toxicities identified in the Phase I trial include diarrhea and hepatotoxicity at higher dose levels of the liposomal formulation, indicating that liver function monitoring would be prudent in any clinical application. Potential drug interactions have not been systematically characterized in humans, but the compound's modulation of cytochrome P450 enzymes in preclinical studies raises theoretical concern for interactions with chemotherapeutics, anticoagulants, and hepatically metabolized drugs; co-administration with hepatotoxic agents should be approached with caution. Safety in pregnancy and lactation has not been evaluated in controlled studies, and given the potent apoptotic and cell cycle-arresting mechanisms demonstrated in vitro, use during pregnancy is not recommended until adequate safety data are available.